Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16013343 | 0.84 | PLA2G2A (0.44) | HRH3PLA2G2ABLM | |
| SCHEMBL16013342 | 0.84 | PLA2G2A (0.44) | HRH3PLA2G2ABLM | |
| SCHEMBL14075734 | 0.84 | HRH3 (0.50) | HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16013562 | 0.83 | HRH3 (0.47) | HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13407789 | 0.82 | HRH3 (0.76) | HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16012595 | 0.82 | PLA2G2A (0.42) | ALDH1A1PLA2G2ABLM | |
| SCHEMBL16012594 | 0.82 | PLA2G2A (0.42) | ALDH1A1PLA2G2ABLM | |
| SCHEMBL16013220 | 0.81 | HRH3 (0.46) | HRH3KDM4EALDH1A1PLA2G2ABLM | |
| SCHEMBL2759077 | 0.81 | PLA2G2A (0.55) | PLA2G2ABLMAHR | |
| SCHEMBL24344637 | 0.81 | HRH3 (0.44) | HRH3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655402-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | Providence Therapeutics Holdings Inc. (CA) | 2025-12-03 | — | — | EP | disclosed |
| EP-4452934-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | Providence Therapeutics Holdings Inc. (CA) | 2024-10-30 | — | — | EP | disclosed |
| WO-2024156053-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024073848-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023137550-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023115221-A1 | IONIZABLE DILSULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |